Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSEAM: ANVS) on behalf of Annovis stockholders. Our investigation concerns whether Annovis has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

Annovis is a clinical-drug company that develops drugs for the treatment of neurodegenerative diseases.

On July 28, 2021, after the market closed, Annovis reported clinical trial data for Posiphen that failed to show statistical significance in treating Alzheimer's and Parkinson's Disease patients relative to a placebo.

Following this news, Annovis’ stock price declined $65.94 per share or over 60% to close at $43.50 on July 29, 2021.

If you purchased or otherwise acquired Annovis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210803006168/en/